Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 8, 2014 - Issue 1
Submit an article Journal homepage
333
Views
7
CrossRef citations to date
0
Altmetric
Drug Profile

Ustekinumab: moving the target from psoriasis to Crohn's disease

Alessia SettesoldiGastroenterologia SOD2, AOU Careggi, Florence, Italy
,
Manuela CoppolaGastroenterologia SOD2, AOU Careggi, Florence, Italy
,
Francesca RogaiGastroenterologia SOD2, AOU Careggi, Florence, Italy
&
Vito AnneseGastroenterologia SOD2, AOU Careggi, Florence, ItalyCorrespondence[email protected]
Pages 5-13 | Published online: 25 Nov 2013

References

  • Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between the north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39, 690–697 (1996).
  • Hiatt RA, Kaufman l. Epidemiology of inflammatory bowel disease in a defined northern California population. Western J. Med. 149:541–546 (1988).
  • Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig. Dis. Sci. 58, 519–525 (2013).
  • Van Assche G, Dignass A, Panes J et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J. Crohns Colitis. 4, 7–27 (2010).
  • Reichert JM. Antibodies to watch in 2010. MAbs 2, 84–100 (2010).
  • Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumor necrosis factor-alpha (TNFalpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin. Exp. Immunol. 94, 354–362 (1993).
  • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244–279 (2008).
  • Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827–845 (1989).
  • Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).
  • Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081–2095 (1989).
  • Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950–957 (2007).
  • Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 30, 646–655 (2009).
  • Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281–1290 (1995).
  • Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
  • Di Meglio P, Di Cesare A, Laggner U et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE 6, 17160 (2011).
  • Benson JM, Peritt D, Scallon BJ et al. Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3, 535–545 (2011).
  • Luo J, Wu SJ, Lacy ER et al. Structural basis for dual recognition of IL-12 and IL-23 by ustekinumab. J. Mol. Biol. 402, 797–812 (2010).
  • Presky DH, Yang H, Minetti LJ et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl Acad. Sci. U.S.A. 93, 14002–14007 (1996).
  • Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715–725 (2000).
  • Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002).
  • Zhu Y, Hu C, Lu M et al. Population pharmacokinetic modelling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49, 162–175 (2009).
  • Kaufman CL, Aria N, Toichi E et al. A Phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037–1044 (2004).
  • Gottlieb AB, Cooper KD, McCormick TS et al. A Phase I, double-blind, placebo-controlled study evaluating single subcutaneous administration of human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23, 1081–1092 (2007).
  • Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
  • Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
  • Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of Ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double blind, placebo-controlled trial (PHOENIX1). Lancet 371, 1665–1674 (2008).
  • Papp KA, Langely RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double blind, placebo-controlled trial (PHOENIX2). Lancet 371, 1675–1684 (2008).
  • Griffiths CEM, Strober B, van de Kerkhof PCM et al. A Phase III multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. European Academy of Dermatology and Venerology Annual Congress Paris. FP1336(2008).
  • McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894), 780–789 (2013).
  • Sandborn WJ, Feagan B, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130–1141 (2008).
  • Cingoz O. Ustekinumab. MAbs 1(3), 216–221 (2009).
  • Sandborn WJ, Gasink C, Gao LL et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the CERTIFI Trial. Gastroenterology 140, 109 (2011).
  • Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease. N. Engl. J. Med. 367, 1519–1528 (2012).
  • Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 496–503 (2012).
  • Tillack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-e(2013)xpressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut (2013) ( Epub ahead of print).
  • Lebwohl M, Leonardi C, Griffiths CEM et al. Long-term safety experience of ustekinumab on patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 66, 731–741 (2012).
  • Gordon KB, Papp KA, Langley RG et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 66, 742–751 (2012).
  • O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 3, 159–168 (2009).
  • Tzellos T, Kyrgidis A, Zomboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with IL-12/23 biologic agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Am. Acad. Dermatol. Venereol. 27, 622–627 (2013).
  • Sands BE, Jacobson EW, Sylwestrowicz T et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm. Bowel Dis. 16, 1209–1218 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.